HANSA BIOPHARMA

Conference Call Presentation

Interim Report Q1 2022

Lund, April 21, 2022

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

HANSA BIOPHARMA

Solid sales growth reported in Q1'22; Market access secured in Germany and France; Marketing authorization granted in Israel

Highlights for the first quarter of 2022

- ✓ Launch activities and market access efforts in EU progressing as planned
  - Solid sales growth in Q1 with SEK 24.2m in product sales; Total revenue of SEK 30.3m
  - Full commercial access secured in Germany on negotiated terms, while market access is granted in France through a reimbursed Early Access Program
  - Market access procedures are ongoing in 11 countries, incl. Spain, Italy and the U.K.
  - Marketing authorization granted for Idefirix® in Israel
- ✓ Key data from a Phase 2 program in anti-GBM patients highlighted in JASN
- ✓ Clinical pipeline
  - Anti-GBM: U.S. FDA has accepted Hansa's Investigational New Drug (IND) application to proceed with a Phase 3 study of imlifidase in 50 anti-GBM patients across U.S. and EU. First patient expected to be enrolled in 2022
  - U.S. ConfIdeS: Patient enrollment on track for completion second half 2022
  - AMR: Patient enrollment on track for completion first half 2022
  - GBS: 16/30 patients enrolled in the GBS phase 2 study; Significant initiatives implemented to support the completion of enrollment of GBS patients in H2 2022
- ✓ Agreement with AskBio (subsidiary of Bayer AG) to evaluate feasibility of imlifidase ahead of gene therapy in Pompe disease
- ✓ Cash position of SEK 754 million end of Q1'22; Hansa is financed into 2023

Full commercial access secured in Germany; Market access granted in France through a reimbursed Early Access Program

Market access procedures ongoing in 11 countries incl. Spain, Italy and the U.K. During 2021 market access was secured in Sweden and Netherlands as well as on an individual hospital basis in Finland and Greece

- Health Technology Assessments (HTA) dossiers submitted
- Marketing Authorization Application submitted
- Pricing & reimbursement obtained (country or clinic level)
- Territories covered commercially by Medison Pharma



[1]Annual kidney transplantations 2019 (pre-Corona)
*Transplantation data is from Global Observatory on Donation and Transplantation, 2019
**Pricing & reimbursement obtained in France on an early access basis

Our center focused and sequenced launch process will help build the foundation for Idefirix® to become a new Standard of Care in transplantation

Idefirix® is the first and only approved treatment in Europe for desensitization treatment of highly sensitized kidney transplant patients. The long-term market uptake is highly dependent on successful early experiences in key early adopter centers

Illustrative



1 Build the foundation for Idefirix® in EU to become a new Standard of Care

- Commercialize in early-launch countries focusing on leading clinics and early adopters
- Secure Pricing and Reimbursement agreements
- Ensure clinical readiness and KOL engagement
- Implement new medical guidelines through ESOT
- Increase awareness on unmet need through KOL engagement, patient organizations and medical conferences
- Initiate post approval study in Europe to support full approval and establish long-term outcomes

"Low initial uptake and volatile growth"

Sales initially remain "low and volatile" between quarters during the initial launch years until early positive experiences are generated for Idefirix® to become a new SoC

2 Expanding internationally will lead to more accelerated growth mid term

- Leverage experience to scale Idefirix in Europe with early-launch centers and in the five largest markets after completing market access
- Launch in the U.S. following completion of the ConfIdeS study and FDA approval
- Expand to select markets and regions beyond core markets in EU and the U.S. through partnerships
- Full marketing authorization in Europe
- Support patient and organ access for highly sensitized patients

"More accelerated growth'

Expand broader and internationally

3 Potential label expansion will enable new growth pockets longer term

- Commercialize in AMR in kidney upon potential approval
- Potentially expand into living donor transplantation
- Potentially expand into other solid organ transplantations such as heart and lung pre- and post transplantation (AMR)

"Growth from pursuing new opportunities"

Potentially enable label expansions

HANSA BIOPHARMA

Results from Phase 2 study of imlifidase in anti-GBM disease published in Journal of American Society of Nephrology Nephrology (JASN)[1]

U.S. FDA has accepted Hansa's Investigational New Drug (IND) application to proceed with a Phase 3 study of imlifidase in 50 patients across U.S. and EU with the first patient is expected to be enrolled in 2022

The JASN publication recognises the potential in deactivation of autoantibodies in autoimmune diseases


CLINICAL RESEARCH www.jasn.org

Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study

Fredrik Uhlin,[1,2] Wladimir Szpirt,[3] Andreas Kronbichler,[4] Annette Bruchfeld,[1,5] Inga Soveri,[6] Lionel Rostaing,[7] Eric Daugas,[8] Arnaud Lionet,[9] Nassim Kamar,[10] Cédric Rafat,[11] Marek Mysliveček,[12] Vladimír Tesař,[12] Anders Fernström,[1] Christian Kjellman,[13] Charlotte Elfving,[13] Stephen McAdoo,[14] Johan Mölne,[15] Ingeborg Bajema,[16] Elisabeth Sonesson,[13] and Mårten Segelmark[1,17]

Due to the number of contributing authors, the affiliations are listed at the end of this article.

ABSTRACT

Background The prognosis for kidney survival is poor in patients presenting with circulating anti-glomerular basement membrane (GBM) antibodies and severe kidney injury. It is unknown if treatment with an endopeptidase that cleaves circulating and kidney bound IgG can alter the prognosis.

Methods An investigator-driven phase 2a one-arm study (EudraCT 2016–004082–39) was performed in 17 hospitals in five European countries. A single dose of 0.25 mg/kg of imlifidase was given to 15 adults with circulating anti-GBM antibodies and an eGFR <15 ml/min per 1.73m². All patients received standard treatment with cyclophosphamide and corticosteroids, but plasma exchange only if autoantibodies rebounded. The primary outcomes were safety and dialysis independency at 6 months.

Results At inclusion, ten patients were dialysis dependent and the other five had eGFR levels between 7 and 14 ml/min per 1.73m². The median age was 61 years (range 19–77), six were women, and six were also
ositive for anti-neutrophil cytoplasmic antibodies. Then 6 hours after imlifidase infusion, all patients had
nti-GBM antibodies levels below the reference range of a prespecified assay. At 6 months 67% (ten out
15) were dialysis independent. This is significantly higher compared with 18% (nine out of 50) in a histori-
control cohort (P<0.001, Fisher's exact test). Eight serious adverse events (including one death
rted, none assessed as probably or possibly related to the study drug.
lusions In this pilot study, the use of imlifidase was associated with a
publications, without major safety issues, but the findi
led trial.

Trial registration number: EUDR
ial/2007-001377-28/

10 out of 15 patients were dialysis independent after six months; The anti-GBM data is significantly better than the historical cohort, where only 18% had functioning kidney



[1] Journal of the American Society of Nephrology https://pubmed.ncbi.nlm.nih.gov/35260419/ Segelmark et al. JASN (2022)

[2] McAdoo et al.: Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 92: 693–702, 2017

Continuous progress in our ongoing clinical Programs

Enrollment status
April 20, 2022

- Patients enrolled
- Patients remaining

Antibody Mediated Rejection Phase 2 study

- 28/30 patients enrolled in the AMR phase 2 study
- Completion of enrollment expected H1 2022*
- First data read out expected in H2 2022*

- Patients enrolled
- Patients remaining

Guillain-Barré Syndrome Phase 2 study

- 16/30 patients enrolled in the GBS phase 2 study
- Enrollment rate has been affected by the COVID-19 pandemic. Significant initiatives are implemented to support the completion of enrollment incl. simplification of the protocol, addition of two new sites and supporting hiring of staff at the clinics
- Completion of enrollment expected in H2 2022*
- First data read out expected in H1 2023

Enrollment status
April 20, 2022

- Patients enrolled
- Patients remaining

Anti-GBM Phase 3 study

- U.S. FDA has accepted Hansa's Investigational New Drug (IND) application to proceed with a Phase 3 study
- The planned study will commence this year* targeting 50 patients across the U.S. and Europe

- Patients enrolled
- Patients remaining

U.S. ConfIdeS Phase 3 study

Randomized, controlled trial in highly sensitized kidney transplant patients across 12-15 centers

- 16/64 patients enrolled for randomization
- Nine centers are active and open for recruitment
- Completion of enrollment expected H2 2022*

Guidance assumes no further escalation of the COVID-19 pandemic potentially forcing trial centers to reprioritize patient recruitment or even shut down again.

HANSA BIOPHARMA

Broad clinical pipeline in transplantation and auto-immune diseases

Candidate/ Program	Indication	Research/ Preclinical	Phase 1	Phase 2	Phase 3	Marketing Authorization	Marketed	Next Anticipated Milestone
Imlifidase	EU: Kidney transplantation in highly sensitized patients [1,2]						*)	EU: Additional agreements around reimbursement from H2'21
	US: Kidney transplantation in highly sensitized patients [1,2]							Completion of enrollment (64 patients) H2'22
	Anti-GBM antibody disease [3]							Pivotal Phase 3 study expected to commence in 2022 (50 patients)
	Antibody mediated kidney transplant rejection (AMR)							Completion of enrollment (30 patients) H1 2022
	Guillain-Barré syndrome (GBS)							Completion of enrollment (30 patients) H2 2022
	Pre-treatment ahead of gene therapy in Limb-Girdle (Partnered with Sarepta)							Preclinical phase
	Pre-treatment ahead of gene therapy in Duchenne (Partnered with Sarepta)							Preclinical phase
	Pre-treatment ahead of gene therapy in Pompe disease (Partnered with AskBio)							Preclinical phase
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology							Completion of GLP toxicology studies in 2022
EnzE	Cancer immunotherapy							Research phase

[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
[3] Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund
*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients. A post-approval study will commence in parallel with the launch

Completed Ongoing
Planned Conditional approval based on Phase 2 data

Solid sales growth in Q1’2022 - product sales of SEK 24.2m





Continued investments in our commercialization and pipeline

SG&A expenses (Q/Q)



R&D expenses (Q/Q)



Net loss (Q/Q)



SG&A expenses (FY/FY)



R&D expenses (FY/FY)



Net loss (FY/FY)



With current cash position and projected burn-rate, Hansa's operations are financed into 2023

Operating cash flow (Q/Q)



Cash & short-term investments (Q/Q)



Shareholders' equity (Q/Q)



Operating cash flow (FY/FY)



Number of employees (Q/Q)



** incl. USD 10 mio (SEK ~90 mio) upfront from Sarepta*

HANSA BIOPHARMA

Upcoming milestones

Milestones subject to potential COVID-19 impact



Guidance assumes no persistent impact or further escalation of the COVID-19 pandemic potentially forcing trial centers to reprioritize patient recruitment or even shut down again.

HANSA BIOPHARMA

Q&A

… at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives…

Visit our web site
www.hansabiopharma.com



HANSA BIOPHARMA

Corporate Contacts

Investor Relations and
Corporate Communications

Visit our web site
www.hansabiopharma.com

Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com

Katja Margell

Head of Corporate Communications

Mobile: +46 (0) 768-198 326

Email: katja.margell@hansabiopharma.com

Calendar and events

April 21 2022	Kempen Life Sciences Conference 2022, Amsterdam
April 27 2022	Redeye Orphan Drugs 2022, Stockholm
May 15 2022	ABG Life Science Summit 2022, Stockholm
May 16 2022	European Midcap Event, Copenhagen
June 16 2022	**Annual General Meeting 2022**
July 12 2022	William Blair's Biotech Focus Conference 2022, New York
July 21 2022	**Half year 2022 report**
Aug 9 2022	BTIG Biotechnology Conference 2022, New York
Aug 10 2022	Canaccord Annual Growth Conference, Boston
Sept 7 2022	Pareto annual Healthcare Conference 2022, Stockholm
Sept 7-8 2022	Citi's 17th Annual BioPharma Conference, Boston
Oct 20 2022	**Interim Report for January-September 2022**
Nov 23 2022	Økonomisk Ugebrev Life Science konference, Copenhagen

HANSA BIOPHARMA


HANSA
BIOPHARMA